Table 5.

Association Between Severe Acute Respiratory Syndrome Coronavirus 2 RNA Results at Days 0 and 3 and Subsequent Hospitalization/Death Through Day 28

Regression Model	Covariate	Comparison	Placebo (n = 478)		mAb-Treated (n = 1353)
			Risk Ratio (95% CI)	P Value	Risk Ratio (95% CI)	P Value
Unadjusted model 1	Day 0 AN RNA	2 log10 copies/mL vs <LLoQ	2.29 (0.20–26.51)	.51	1.03 (0.11–9.95)	.98
		Per 1 log10 copies/mL above LLoQ higher	1.35 (0.96–1.91)	.0840	1.39 (1.09–1.76)	.0071
Unadjusted model 2	Day 3 AN RNA	2 log10 copies/mL vs <LLoQ	0.54 (0.12–2.37)	.41	2.17 (0.58–8.15)	.25
		Per 1 log10 copies/mL above LLoQ higher	1.59 (1.15–2.19)	.0047	1.17 (0.81–1.67)	.40
Mutually adjusted model	Day 0 AN RNA	2 log10 copies/mL vs <LLoQ	4.06 (0.29–56.66)	.30	0.98 (0.09–10.35)	.99
		Per 1 log10 copies/mL above LLoQ higher	1.28 (0.82–1.98)	.28	1.33 (1.01–1.76)	.0456
	Day 3 AN RNA	2 log10 copies/mL vs <LLoQ	0.22 (0.03–1.58)	.13	1.29 (0.33–5.15)	.71
		Per 1 log10 copies/mL above LLoQ higher	1.42 (1.00–2.03)	.0526	1.02 (0.68–1.56)	.91

“<LLoQ” represents results below the lower limit of quantification (2 log₁₀ copies/mL). Event outcome was hospitalization or death between days 4 and 28. Analyses were restricted to participants with no event before or on day 3.

Unadjusted models 1 and 2 include covariates corresponding to day 0 AN RNA only and day 3 AN RNA only, respectively. The mutually adjusted model includes covariates corresponding to both day 0 and day 3 AN RNA. Separate models were fit for each arm (mAb-treated and placebo). For the day 3 AN RNA only model involving placebo recipients, the 95% CIs and 2-sided Wald test P values are from Poisson regression due to convergence issues with log-binomial regression. All other 95% CIs and 2-sided Wald test P values are from log-binomial regression. Risk ratios with 95% CIs that do not include 1 are bolded.

Abbreviations: AN, anterior nasal; CI, confidence interval; LLoQ, lower limit of quantification; mAb, monoclonal antibody.